No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Chemicals - Specialty
Chengzhi Shareholding Co., Ltd. engages in diverse business operations within China, encompassing clean energy, advanced functional materials, healthcare, and biotechnological fields. The company supplies specialized materials, such as liquid crystal and various chemicals essential for display technologies, alongside a range of daily and niche chemical products. Its extensive portfolio also includes edible fats and oils, a wide array of paper goods (including sanitary and household items), components for the automotive, machinery, and electronics industries, and biopharmaceutical products. Additionally, Chengzhi provides services in consulting, property management, and hospital investment management. Established in 1998, the company's main office is located in Nanchang, China.
www.chengzhi.com.cnNo one on the platform currently holds 000990.SZ.
No tracked institution reports a position in 000990.SZ as of their last filing.
No one on the platform has traded 000990.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -0.3% | 2.5% | ||||
| Profit Margin % | -0.7% | 2.3% | 5.5% | |||
| Free Cash Flow Margin % | 2.3% | 5.4% | 4.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $14.8B | +25.9% | $0.49 | $0.49–$0.49 | — | 1 |
| 2027 | $16.0B | +7.6% | $0.54 | $0.54–$0.54 | — | 1 |
| 2028 | $17.1B | +7.1% | $0.61 | $0.61–$0.61 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 000990.SZChengzhi Shareholding Co., Ltd. | $6.42 | +1.10% | $10.9B | — |
| 002030.SZDaan Gene Co., Ltd. | $5.22 | +0.19% | $7.3B | — |
| 002275.SZGuilin Sanjin Pharmaceutical Co., Ltd. | $12.09 | -0.41% | $7.1B | — |
| 300841.SZChengdu Kanghua Biological Products Co., Ltd. | $49.37 | +0.80% | $6.4B | — |
| 603229.SSZhejiang Ausun Pharmaceutical Co., Ltd. |
| $7.56 |
| +0.00% |
| $6.3B |
| — |
| 605116.SSAurisco Pharmaceutical Co.,Ltd. | $19.02 | +0.26% | $7.7B | — |
| 688105.SSNanjing Vazyme Biotech Co., Ltd. | $20.12 | -0.20% | $10.4B | — |
Source: Financial Modeling Prep · peers by sector/industry